Results 271 to 280 of about 24,793 (292)
Some of the next articles are maybe not open access.
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
The Lancet Oncology, 2020 O. Al-Sawaf, Can Zhang, M. Tandon, Arijit Sinha, A. Fink, S. Robrecht, O. Samoylova, A. Liberati, J. Pinilla-Ibarz, Stephen Samuel Opat, L. Sivcheva, K. Le Dû, L. Fogliatto, C. Niemann, R. Weinkove, S. Robinson, T. Kipps, E. Tausch, W. Schary, M. Ritgen, C. Wendtner, K. Kreuzer, B. Eichhorst, S. Stilgenbauer, M. Hallek, K. Fischer +25 moresemanticscholar +1 more sourceStudies of chlorambucil—DNA adducts
Biochemical Pharmacology, 1992 Chlorambucil (CLB) is a bifunctional nitrogen mustard whose therapeutic and major side-effects are thought to be caused by binding to DNA. HPLC analysis of hydrolyzed DNA from L1210 cells incubated with [14C]CLB generated two peaks of radioactivity, indicating the formation of two or more major adducts.openaire +3 more sourcesIbrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
The Lancet Oncology, 2019 C. Moreno, R. Greil, F. Demirkan, A. Tedeschi, B. Anz, L. Larratt, M. Šimkovič, O. Samoilova, J. Novak, D. Ben-yehuda, V. Strugov, D. Gill, J. Gribben, E. Hsu, C. Lih, Cathy Zhou, F. Clow, D. James, L. Styles, I. Flinn +19 moresemanticscholar +1 more source
